Investigational Drug Information for Rimiducid
✉ Email this page to a colleague
What is the drug development status for Rimiducid?
Rimiducid is an investigational drug.
There have been 22 clinical trials for Rimiducid.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 27th 2018.
The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Neoplasms, and Preleukemia. The leading clinical trial sponsors are Bellicum Pharmaceuticals, Poseida Therapeutics, Inc., and National Cancer Institute (NCI).
There are seven US patents protecting this investigational drug and eighty-seven international patents.
Summary for Rimiducid
| US Patents | 7 |
| International Patents | 87 |
| US Patent Applications | 76 |
| WIPO Patent Applications | 81 |
| Japanese Patent Applications | 25 |
| Clinical Trial Progress | Phase 1 (2018-12-27) |
| Vendors | 41 |
Recent Clinical Trials for Rimiducid
| Title | Sponsor | Phase |
|---|---|---|
| Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Bellicum Pharmaceuticals | Phase 1 |
| Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | M.D. Anderson Cancer Center | Phase 1 |
| P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | Poseida Therapeutics, Inc. | Phase 1 |
Clinical Trial Summary for Rimiducid
Top disease conditions for Rimiducid
Top clinical trial sponsors for Rimiducid
US Patents for Rimiducid
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| rimiducid | ⤷ Sign Up | Compositions and methods for treatment of cancer | Aleta Biotherapeutics Inc. (Natick, MA) | ⤷ Sign Up |
| rimiducid | ⤷ Sign Up | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| rimiducid | ⤷ Sign Up | Treatment of cancer using GFR .alpha.-4 chimeric antigen receptor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA) NOVARTIS AG (Basel, CH) THE SCRIPPS RESEARCH INSTITUTE (La Jolla, CA) | ⤷ Sign Up |
| rimiducid | ⤷ Sign Up | Treatment of cancer using a CD33 chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| rimiducid | ⤷ Sign Up | Synthetic multimerizing agents | ARIAD Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| rimiducid | ⤷ Sign Up | Synthetic multimerizing agents | ARIAD Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| rimiducid | ⤷ Sign Up | Treatment of cancer using a CD33 chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Rimiducid
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| rimiducid | Australia | AU2016343809 | 2035-10-30 | ⤷ Sign Up |
| rimiducid | Brazil | BR112018008326 | 2035-10-30 | ⤷ Sign Up |
| rimiducid | Canada | CA3002674 | 2035-10-30 | ⤷ Sign Up |
| rimiducid | Chile | CL2018001152 | 2035-10-30 | ⤷ Sign Up |
| rimiducid | China | CN108602872 | 2035-10-30 | ⤷ Sign Up |
| rimiducid | European Patent Office | EP3368559 | 2035-10-30 | ⤷ Sign Up |
| rimiducid | Israel | IL258955 | 2035-10-30 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
